Phase 2 Trial of Dose Dense (Weekly) Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 20 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 10 Jun 2017 Biomarkers information updated